"","Num","POD","SD","%","Genes","KE"
"CARCINOMA","2","0.400048187089489","0.498328831817071","40","dkc1, ptenb","PROMOTION HEPATOCELLUAR CARCINOMA"
"ELEVATED RED CELL ADENOSINE DEAMINASE LEVEL","6","0.831824226955995","0.162056330099067","33.33","rpl15, rpl26, rpl35, rps15a, rps26l, rps29","INCREASED CYCLIC ADENOSINE MONOPHOSPHATE"
"PURE RED CELL APLASIA","6","0.831824226955995","0.162056330099067","30","rpl15, rpl26, rpl35, rps15a, rps26l, rps29","N/A METHEMOGLOBINEMIA DECREASED HEMOGLOBIN HEMATOCRIT RED BLOOD CELL NUMBER"
"GLOMERULAR SCLEROSIS","2","1.41253117279502","0.0689392493333263","14.29","nup107, nup85","DECREASED GLOMERULAR FILTRATION"
"CYTOPLASMIC RIBOSOMAL PROTEINS","10","1.76593719818759","0.1036575238762","6.94","rpl13a, rpl15, rpl26, rpl35, rpl39, rpl7, rps15a, rps26l, rps29, rps8a","OCCURRENCE CYTOPLASMIC VACUOLIZATION PODOCYTE"
"LOCOMOTORY BEHAVIOR","3","1.90749559417752","0.57095456919735","4.84","adora2aa, hoxb8a, ptenb","REDUCED SWIMMING SPEED; REDUCED SWIMMING PERFORMANCE"
"REGULATION OF PH","3","1.98269290843715","0.498951425826144","21.43","atp6ap1b, atp6v1e1b, mapk3","DECREASE INTRACELLULAR PH"
"ABNORMAL CIRCULATING ESTROGEN LEVEL","2","2.10551797425475","0.191523926011453","14.29","cyb5a, nup107","INCREASED CIRCULATING ESTROGEN LEVELS"
"GO:0046562","3","2.20820009424641","0.29148406749179","11.11","eno1a, ldha, pck2","DECREASED GLUCOSE OXIDASE ENZYME ACTIVITY"
"GO:0008283","3","2.29545881101446","0.521441825286191","33.33","hoxb8a, mif, tacc3","PROLIFERATION CELL PROLIFERATION IN THE ABSENCE OF CYTOTOXICITY; ACTIVATION/PROLIFERATION T-CELLS; ALTERATIONS CELLULAR PROLIFERATION / HYPERPLASIA; INCREASE PROLIFERATION LEYDIG CELL; INCREASE MITOGENIC CELL PROLIFERATION HEPATOCYTES; INCREASE HYPERTROPHY AND PROLIFERATION FOLLICULAR CELL; INCREASE REGENERATIVE CELL PROLIFERATION CORNEAL CELLS; INCREASE REGENERATIVE CELL PROLIFERATION FORESTOMACH EPITHELIAL CELLS; INCREASE REGENERATIVE CELL PROLIFERATION HEPATOCYTES; INCREASE REGENERATIVE CELL PROLIFERATION UROTHELIAL CELLS; INCREASE CELL PROLIFERATION; INCREASE PROLIFERATION OF GOBLET CELLS; INCREASED HYPERTROPHY AND PROLIFERATION FOLLICULAR CELL; PROLIFERATION/CLONAL EXPANSION SMOOTH MUSCLE; INCREASED CELLULAR PROLIFERATION / HYPERPLASIA OF ACINAR CELLS; PROLIFERATION/CLONAL EXPANSION ABERRANT BASAL CELLS; INCREASED CELL PROLIFERATION MESOTHELIUM; INCREASE CELL PROLIFERATION EPITHELIAL CELLS"
"GO:0042701","4","2.76648722220013","0.158828414532696","11.76","akt3a, mapk12a, mapk3, prkacaa","DECREASED PROGESTERONE FROM CORPUS LUTEUM"
"SQUAMOUS CELL CARCINOMA","3","2.79324938124674","0.451615069154583","30","ctsc, dkc1, tars","INCREASE PAPILLOMAS/CARCINOMAS SQUAMOUS CELLS; INCREASE RESPIRATORY OR SQUAMOUS METAPLASIA; SQUAMOUS METAPLASIA ABERRANT BASAL CELLS"
"GO:0008137","2","3.01336539383672","0.452033860004947","22.22","C24H11orf65, ndufc2","INHIBITION NADH-UBIQUINONE OXIDOREDUCTASE COMPLEX I"
"BREAST CANCER PATHWAY","9","3.42962227571721","0.067997946884278","7.89","akt3a, fgf3, fgfr1b, mapk3, nras, ptenb, skp1, tcf7l1a, wnt3a","N/A BREAST CANCER"
"LIPID ACCUMULATION IN HEPATOCYTES","7","3.79689600772765","0.141224486105095","21.88","atp6ap1b, cpt2, hmgcl, lipf, pck2, sar1b, tars","INCREASE PRENEOPLASTIC FOCI HEPATOCYTES"
"GO:0044414","7","3.80051669600183","0.157903460758722","17.5","atp6ap1b, atp6v1e1b, rab5ab, rac1a, sec61al2, sec61g, tubb2","SUPPRESSION IMMUNE SYSTEM"
"INCREASED SUSCEPTIBILITY TO FRACTURES","7","3.82507987649274","0.152914171716342","20","ctsk, dkc1, fgfr1b, nras, ptenb, scn1lab, wnt3a","INCREASED DISEASE SUSCEPTIBILITY"
"G TGF BETA SIGNALING PATHWAY","4","4.38126211473666","0.153717007186235","5.88","mapk3, ppp2r1b, skp1, tgfb2","ACTIVATION TGF-BETA PATHWAY; UP REGULATION TGFBETA1 EXPRESSION"
"GO:0006412","13","4.41497015466109","0.0634708891048819","12.04","eif2b4, eif3ea, eif4a1a, eif4a1b, eif4e2rs1, rpl13a, rpl15, rpl35, rpl39, rps15a, rps26l, rps29, rps8a","ALTERED PROTEIN PRODUCTION"
"CTOME SIGNALING BY TYPE 1 INSULIN LIKE GROWTH FACTOR 1 RECEPTOR IGF1R","4","4.47487550811394","0.17629409644466","30.77","fgf3, fgfr1b, fgfr4, nras","INCREASED IGF-1 MOUSE"
"MATING BEHAVIOR","2","4.693697453049","0.257853129778914","22.22","ptenb, thraa","REDUCED ABILITY TO ATTRACT SPAWNING MATES"
"REPRODUCTIVE BEHAVIOR","2","4.693697453049","0.257853129778914","20","ptenb, thraa","REDUCED SPAWNING BEHAVIOR"
"NEOPLASM OF THE SKIN","6","4.86303865041703","0.160531809414235","18.18","ctsc, dkc1, fgfr1b, nras, ptenb, tars","SENSITISATION SKIN"
"ABNORMALITY OF ADRENAL PHYSIOLOGY","4","4.89521750716167","0.098369531883643","4.35","lipf, nr3c1, rbm28, snrpb","INCREASE RENAL PATHOLOGY DUE TO VTG DEPOSITION; DECREASED RENAL ABILITY TO DILUTE URINE; OCCURRENCE KIDNEY TOXICITY; INCREASED KIDNEY FAILURE"
"GO:1904019","3","5.03277409036346","0.201350629296153","13.64","hmox1a, nfe2l2a, tek","DECREASE APOPTOSIS OF CILIATED EPITHELIAL CELLS"
"DNA DAMAGE RESPONSE","4","5.19598005306583","0.134012407552381","6.9","apaf1, rpa2, tlk2, ywhaqb","INCREASED DNA DAMAGE-REPAIR"
"GO:0016055","4","5.36366484017155","0.174856981094412","17.39","fzd7a, ta, tcf7l1a, wnt3a","ALTERATION WNT PATHWAY"
"GO:0006120","5","5.36385901433122","0.139549945497267","18.52","C24H11orf65, ndufa11, ndufb2, ndufc2, ndufv2","BINDING OF INHIBITOR NADH-UBIQUINONE OXIDOREDUCTASE COMPLEX I"
"ABNORMAL RENAL TUBULE MORPHOLOGY","2","5.37789068079215","0.479495295718471","22.22","cpt2, nup107","OCCURRENCE CYSTIC DILATATION RENAL TUBULE; OCCURRENCE CYTOPLASMIC VACUOLIZATION RENAL TUBULE"
"SIGNALING OF HEPATOCYTE GROWTH FACTOR RECEPTOR","4","5.56529661753876","0.0844491130038754","11.76","mapk3, ptenb, rap1aa, src","OCCURRENCE CYTOPLASMIC VACUOLIZATION HEPATOCYTE; OCCURRENCE BALLOONING DEGENERATION HEPATOCYTE"
"DECREASED BODY WEIGHT","35","5.72849961354724","0.0239701189638583","15.49","ahcy, atp6v1e1b, cdc6, cyb5a, cyb5r3, dhcr7, dkc1, dpm1, echs1, exosc9, fgfr1b, flt1, hmgcl, lipf, ndufa11, ndufv2, nfe2l2a, nfkb1, nup188, pdhx, phgdh, ptenb, puf60a, rpl15, rpl26, rpl35, rps15a, rps26l, rps29, sar1b, scn1lab, snrpb, srp54, stag1b, sucla2","DECREASED BODY WEIGHT"
"ABNORMALITY OF THE PITUITARY GLAND","7","5.86214381021398","0.0751013634426033","14.58","cyb5a, fgfr1b, nup107, puf60a, rbm28, snrpb, srp54","INCREASED ADENOMAS PITUITARY"
"G OOCYTE MEIOSIS","7","6.06566665998235","0.0650145338499963","17.5","calm1b, calm3a, fbxo5, mapk3, ppp2r1b, skp1, ywhaqb","REDUCED MEIOTIC PROPHASE I/METAPHASE I TRANSITION OOCYTE"
"ABNORMALITY OF BLOOD AND BLOOD FORMING TISSUES","42","6.13019539043195","0.0212521949857176","10.4","ahcy, atp6ap1b, atp6v1e1b, cdc42, cpt2, ctsk, cyb5a, cyb5r3, dhfr, dkc1, dpm1, echs1, flt1, gsr, hmgcl, hmox1a, hyou1, ivd, lipf, ndufv2, nfkb1, nras, phgdh, plod1a, ptenb, puf60a, rpl15, rpl26, rpl35, rps15a, rps26l, rps29, rras, sar1b, scn1lab, src, srp54, stk11, tars, tek, tgfb2, thraa","DAMAGING RED BLOOD CELLS; HEMOLYSIS"
"LIPID METABOLISM PATHWAY","2","6.28459334819337","0.14657550826069","16.67","akt3a, fasn","DAMAGE LIPID BILAYER"
"GO:0045333","7","6.73081096964041","0.0867186755342348","9.72","C24H11orf65, ndufa11, ndufb2, ndufc2, ndufv2, sucla2, uqcrc1","INCREASE OXIDATIVE METABOLISM"
"DECREASED FERTILITY","6","6.87539500785433","0.0824728734095261","7.89","cyb5a, fgfr1b, nr3c1, nup107, snrpb, stub1","IMPAIRED FERTILITY; DECREASED SPERM QUANTITY OR QUALITY IN THE ADULT DECREASED FERTILITY; REDUCTION CUMULATIVE FECUNDITY AND SPAWNING; DECREASED SPERM QUANTITY OR QUALITY IN THE ADULT DECREASED FERTILITY; DECREASED SPERM QUANTITY OR QUALITY IN THE ADULT DECREASED FERTILITY; DECREASED TESTOSTERONE"
"ABNORMAL LIVER MORPHOLOGY","22","7.00691561975015","0.042529044383701","18.49","atp6ap1b, cpt2, ctsc, ctsk, dhfr, dkc1, dpm1, flt1, hmgcl, hmox1a, hyou1, lipf, mif, ndufa11, ndufv2, nras, pck2, ptenb, rras, sar1b, srp54, tars","INDUCTION LIVER “DYSFUNCTIONAL” CHANGES BY CGA 330050; INFLAMMATION LIVER; N/A LIVER FIBROSIS; INCREASE RBC CONGESTION IN LIVER; INCREASE LIVER AND SPLENIC HEMOSIDEROSIS; REDUCTION VITELLOGENIN SYNTHESIS IN LIVER; INCREASE VITELLOGENIN SYNTHESIS IN LIVER; FORMATION LIVER FIBROSIS; FORMATION LIVER TUMOR"
"GO:0007051","7","7.02232464723564","0.13579983720137","25.93","fbxo5, nek2, ppp2r1b, rae1, ran, tacc3, ttk","DISORGANIZATION SPINDLE"
"PYRUVATE METABOLIC PROCESS","11","7.09944824243565","0.0710669375473913","19.64","eno1a, ldha, nup107, nup188, nup43, nup85, ogdhb, pck2, pdhx, pparab, rae1","INHIBITION 4-HYDROXYPHENYL-PYRUVATE DIOXYGENASE HPPD ENZYME"
"ABNORMAL NASAL MORPHOLOGY","30","7.12790957109641","0.0295043457252598","19.35","akt3a, atp6v1e1b, cdc42, cpt2, ctsd, ctsk, dhcr7, dpm1, fgf3, fgfr1b, hyou1, impdh1b, nek2, nras, nup188, plod1a, ppp2r1b, ptenb, puf60a, rac1a, rpl15, rpl26, rpl35, rps15a, rps26l, rps29, scn1lab, snrpb, stag1b, tlk2","INCREASE SITE OF CONTACT NASAL TUMORS"
"GO:0006635","4","7.2020314687378","0.158108616069382","20","cpt2, echs1, ivd, pparab","DECREASED PEROXISOMAL FATTY ACID BETA OXIDATION OF FATTY ACIDS; DECREASED MITOCHONDRIAL FATTY ACID BETA OXIDATION; DECREASED MITOCHONDRIAL FATTY ACID BETA-OXIDATION; INHIBITION MITOCHONDRIAL FATTY ACID BETA-OXIDATION"
"GO:0016310","19","7.28917691480779","0.0468323850814021","15.2","akt3a, ckbb, csnk1g2a, EPHA2_2of2, fgfr1b, fgfr4, flt1, insra, mapk12a, mapk3, nek2, prkacaa, sephs1, skp1, src, stk11, tek, tlk2, ttk","ACTIVATION SP1"
"ABNORMAL SOCIAL BEHAVIOR","5","7.3686088913244","0.0854689587035288","19.23","ndufa11, ndufv2, puf60a, snrpb, tars","ABNORMAL FORAGING ACTIVITY AND BEHAVIOR"
"ABNORMAL BLOOD POTASSIUM CONCENTRATION","2","7.42479669231591","0.104150973829542","16.67","calm3a, nr3c1","INCREASED BLOOD POTASSIUM CONCENTRATION"
"GO:0030545","5","7.63098037595262","0.21098935124894","8.47","adcyap1b, fgf3, mif, tgfb2, wnt3a","DESENSITIZATION NICOTINIC ACETYLCHOLINE RECEPTOR"
"POSITIVE REGULATION OF GENE EXPRESSION","21","7.65062774209128","0.038235655711818","11.6","adcyap1b, cebpb, eif3ea, eno1a, fgf3, fgfr4, hmox1a, mapk3, mif, nfe2l2a, nfkb1, polr2eb, polr2l, polr3d, ptenb, rpl26, src, vegfaa, wnt3a, xbp1, znrd1","ALTERED GENE EXPRESSION"
"ENDOMETRIAL CANCER","6","7.84619607351076","0.0606568105198594","8.82","akt3a, fgfr1b, mapk3, nras, ptenb, tcf7l1a","INCREASE ENDOMETRIAL ADENOCARCINOMAS"
"HUMAN THYROID STIMULATING HORMONE TSH SIGNALING PATHWAY","4","7.86483441717776","0.0423229098908727","3.7","gna12a, mapk3, rap1aa, src","DECREASED TRIIODOTHYRONINE T3 IN SERUM; INCREASE THYROID-STIMULATING HORMONE TSH; DECREASED THYROXINE T4 IN SERUM; INCREASED THYROID-STIMULATING HORMONE TSH"
"GO:0043542","7","7.97017077355213","0.0613952872210772","20","akt3a, EPHA2_2of2, fgfr1b, hmox1a, lgmn, nfe2l2a, tek","INCREASED MIGRATION ENDOTHELIAL CELLS"
"HEART DEVELOPMENT","15","8.09942135610083","0.0559632636215358","11.9","ap2b1, bves, cdc42, fgf3, mapk3, ndufv2, pcna, pparab, ptenb, slc8a1a, tbx20, tek, tgfb2, vegfaa, wnt3a","ALTERED LARVAL DEVELOPMENT; IMPAIRED DEVELOPMENT"
"ELECTRON TRANSPORT CHAIN","10","8.12032560608854","0.0635772679897235","14.71","C24H11orf65, cyb5a, gsr, ndufa11, ndufb2, ndufc2, ndufv2, p4ha2, phgdh, uqcrc1","DISRUPTION MITOCHONDRIAL ELECTRON TRANSPORT CHAIN"
"ABNORMALITY OF THE LIVER","26","8.2602235252027","0.0359617715820308","3.47","ahcy, atp6ap1b, cpt2, ctsc, ctsk, dhcr7, dhfr, dkc1, dpm1, flt1, hmgcl, hmox1a, hyou1, lipf, mif, ndufa11, ndufv2, nfkb1, nras, pck2, ptenb, rras, sar1b, srp54, stk11, tars","INCREASED INDUCTION OF UDPGT'S IN LIVER; INCREASED LIVER STEATOSIS; INCREASED LIVER STEATOSIS; N/A HEPATOTOXICITY HEPATOPATHY INCLUDING A CONSTELLATION OF OBSERVABLE EFFECTS; INDUCTION SUSTAINED HEPATOTOXICITY"
"ABNORMAL CARDIAC TEST","2","8.48953502822224","0.0629978269863071","15.38","calm3a, tbx20","INCREASED CARDIAC ARRTHYMIA"
"ABNORMALITY OF THE MITOCHONDRION","7","8.54921828618949","0.0659161711094596","5.56","cpt2, echs1, hmgcl, ndufa11, ndufv2, pdhx, sucla2","INJURY MITOCHONDRIA; DAMAGING MITOCHONDRIA; N/A MITOCHONDRIAL DYSFUNCTION 1"
"ABNORMALITY OF THE ABDOMINAL ORGANS","28","8.61165518809432","0.0322490255047114","16.57","ahcy, atp6ap1b, cpt2, ctsc, ctsk, dhcr7, dhfr, dkc1, dpm1, flt1, hmgcl, hmox1a, hyou1, lipf, mif, ndufa11, ndufv2, nfkb1, nras, pck2, ptenb, puf60a, rras, sar1b, srp54, stk11, stub1, tars","IMPAIRED DEVELOPMENT OF REPRODUCTIVE ORGANS"
"GO:0019882","8","8.78821167294231","0.0680193056421804","13.56","ap2b1, ctsd, lgmn, psmc1a, psmd10, psmd13, psmd4a, sar1b","GENERATION OF NOVEL EPITOPES  ANTIGEN PRESENTATION"
"GO:0007059","11","9.02056545741735","0.0788546315591302","25","cdc42, cdc6, fbxo5, nek2, nr3c1, nup43, ppp2r1b, ran, tacc3, tlk2, ttk","INCREASED CHROMOSOME MISSEGGREGATION"
"ABNORMAL CIRCULATING CHOLESTEROL CONCENTRATION","4","9.28525778177721","0.18705577758348","36.36","dhcr7, lipf, nup107, sar1b","DECREASED CHOLESTEROL; PERTURBATION OF CHOLESTEROL"
"LIVER X RECEPTOR PATHWAY","2","9.38902375766243","0.269854807239232","16.67","cyp3c1, fasn","ACTIVATION LXR; ACTIVATION LXR ALPHA"
"CHOLESTASIS","5","9.54218425040126","0.286798503359173","14.29","atp6ap1b, dhcr7, dhfr, hmgcl, lipf","INCREASED CHOLESTASIS; CHOLESTASIS PATHOLOGY"
"GO:0004882","7","9.75851259508323","0.0586657028460419","20","nr3c1, pou2f1b, ptenb, ran, rchy1, src, stub1","N/A ANDROGEN RECEPTOR ANTAGONISM; AGONISM ANDROGEN RECEPTOR; DECREASED ANDROGEN RECEPTOR ACTIVITY; ACTIVATION ANDROGEN RECEPTOR"
"TUBE FEEDING","4","9.83868906733868","0.0801659578646342","23.53","fgfr1b, ppp2r1b, puf60a, snrpb","INHIBITION FEEDING"
"UPPER MOTOR NEURON DYSFUNCTION","24","9.8719556520337","0.0294279409409301","5.06","atp6v1e1b, ctsd, cyb5a, cyb5r3, dhcr7, dkc1, echs1, eif2b4, exosc9, fgfr1b, hmgcl, impdh1b, ndufv2, nup107, ogdhb, pdhx, phgdh, ptenb, rbm28, scn1lab, stub1, sucla2, tars, tubb2","DECREASE HISTAMINERGIC NEURON EXCITATION; OCCURRENCE CYTOPLASMIC VACUOLIZATION BILE DUCT CELL; OCCURRENCE CYTOPLASMIC VACUOLIZATION KUPFFER CELL"
"GO:0005488","164","9.93180522844434","0.00455062632717773","15.24","adcyap1b, akt3a, ap2b1, apaf1, bcl2a, bmp2b, bves, calm3a, cdc42, cdc6, cebpb, chpt1, ckbb, cops5, cpsf1, cpsf6, csnk1g2a, cyb5a, cyb5r3, cyp2ad3, cyp3c1, cyp51, dhcr7, dhfr, dkc1, dnaja2, EIF1B, eif2b4, eif3ea, eif4a1a, eif4a1b, eif4e2rs1, eif5b, eno1a, EPHA2_2of2, exosc9, fasn, fbxo5, fgf3, fgfr1b, fgfr4, flt1, fstb, fzd7a, gbx2, gcat, gna12a, gosr2, gsr, hbbe3, hmox1a, hoxb5a, hoxb8a, hsp90b1, hyou1, igfbp2a, impdh1b, insra, ivd, llgl2, lsm8, mapk12a, mapk3, mef2ca, mmp11b, mmp17b, mmp24, mmp28, ndufv2, nek2, nfe2l2a, nfkb1, nhp2l1b, nploc4, nr2f5, nr3c1, nras, ogdhb, onecut1, orc3, p4ha2, pa2g4b, papss2b, pcdh17, pck2, pcna, phgdh, plod1a, pold2, polr2c, polr2eb, polr2l, polr3d, pou2f1b, pparab, ppat, ppm1aa, ppp1caa, prkacaa, psmc1a, psmd4a, psmg1, ptges3a, ptgs2a, puf60a, rab5ab, rac1a, rae1, ran, rap1aa, rbm28, rchy1, rfc5, rhoaa, rnf2, robo3, rpa2, rpl13a, rpl15, rpl35, rpl7, rps26l, rps29, rras, rxrab, sar1b, sec61al2, sephs1, sf3b5, skp1, snrpb, snrpf, sox9b, src, srp54, srprb, srsf2b, stag1b, stk11, stub1, sucla2, ta, taf11, tardbp, tars, tbx20, tcf7l1a, tek, tgfb2, thop1, thraa, thrab, tlk2, tomm34, tradd, ttk, tubb2, u2af2b, uqcrc1, usf1l, utp6, vegfaa, wnt3a, xbp1","INCREASED BINDING OF CHEMICALS TO 2U SERUM"
"REGULATION OF PROTEOLYSIS","19","9.96844706065676","0.0267950345874393","16.96","adora2aa, apaf1, ctsc, ctsd, eno1a, fgfr4, gna12a, lgmn, nfe2l2a, psmd10, ptenb, rchy1, src, stub1, tlk2, tradd, vegfaa, wnt3a, ywhaqb","IMPAIRED PROTEOSTASIS"
"GO:0030163","21","10.1028945523028","0.0234440621217375","13.73","ap2b1, ctsc, ctsd, ctsk, cyp51, fbxo5, gna12a, hsp90b1, lgmn, nfe2l2a, nploc4, psmc1a, psmd10, psmd13, psmd4a, rchy1, skp1, stub1, tlk2, ube4b, xbp1","INCREASED CATABOLISM OF MUSCLE PROTEIN"
"GO:0004872","22","10.1915405488188","0.037372986035223","9.21","adcyap1b, adora2aa, bmp2b, EPHA2_2of2, fgf3, fgfr1b, fgfr4, flt1, fzd7a, gria4b, insra, nr2f5, nr3c1, paqr3a, pparab, rxrab, tek, tgfb2, thraa, thrab, vegfaa, wnt3a","ACTIVATION PXR/SXR"
"PEPTIDYL LYSINE MODIFICATION","7","10.4290819998214","0.107035790010581","9.86","mapk3, nup107, nup188, nup43, nup85, plod1a, rae1","N/A COVALENT BINDING TO PROTEIN POSSIBLY LYSINE RESIDUE"
"GO:0072358","17","10.5296100432564","0.0443053632311069","15.32","akt3a, ap2b1, cdc42, dhcr7, EPHA2_2of2, fgfr1b, flt1, gbx2, hmox1a, nfe2l2a, rap1aa, rras, stk11, tbx20, tek, tgfb2, xbp1","ALTERED CARDIOVASCULAR DEVELOPMENT/FUNCTION"
"GO:0003707","3","10.6599885139084","0.100081176725093","9.38","nr3c1, pparab, thraa","REDUCED MATURATION INDUCING STEROID RECEPTOR SIGNALLING OOCYTE"
"NUCLEAR RECEPTORS","3","10.6599885139084","0.100081176725093","5.77","nr3c1, pparab, thraa","ACTIVATION HEPATIC NUCLEAR RECEPTORS"
"GO:0001525","5","10.6611870661707","0.15644081855906","13.51","flt1, igfbp2a, rps29, tek, vegfaa","REDUCTION ANGIOGENESIS; INCREASED ANGIOGENESIS"
"CTOME SIGNALING BY EGFR","3","10.7371982215855","0.0441638008984361","37.5","cdc42, nras, src","ACTIVATION EGFR"
"CTOME ACTIVATION OF BAD AND TRANSLOCATION TO MITOCHONDRIA","2","10.7854096833327","0.0192830800322828","18.18","akt3a, ywhaqb","DIRECT MITOCHONDRIAL INHIBITION; MITOCHONDRIAL IMPAIRMENT"
"ABNORMAL RESPIRATORY SYSTEM MORPHOLOGY","29","11.076651420572","0.0261951396845904","19.73","atp6v1e1b, cdc42, ctsc, ctsk, dhcr7, dkc1, exosc9, fgfr1b, lipf, mif, nfe2l2a, nfkb1, nras, nup107, phgdh, plod1a, ptenb, puf60a, rac1a, rps15a, rras, scn1lab, snrpb, srp54, stk11, sult2st3, tars, tbx20, tgfb2","INCREASED RESPIRATORY DISTRESS/ARREST"
"G VEGF SIGNALING PATHWAY","7","11.2577872540675","0.0271438901746832","33.33","akt3a, cdc42, mapk3, nras, rac1a, src, vegfaa","REDUCED PRODUCTION VEGF"
"GO:0006629","37","11.3024247433292","0.0216083088234322","17.96","cdc42, chpt1, cpt2, crls1, csnk1g2a, cyb5r3, cyp3c1, cyp51, dhcr7, dpm1, echs1, fasn, fgfr1b, fgfr4, flt1, hmgcl, ivd, lgmn, lipf, mapk3, mif, nfkb1, pck2, pigx, pparab, ppp2r1b, ptges3a, rab5ab, ran, rdh10a, src, stub1, sult2st3, tek, thraa, tspo, xbp1","ALTERATION LIPID METABOLISM"
"GO:0099536","9","11.3044898680684","0.0818754765988782","8.11","adcyap1b, adora2aa, lgmn, pcdh17, rab5ab, rap1aa, src, tubb2, wnt3a","DECREASED NEURONAL NETWORK FUNCTION IN ADULT BRAIN; DECREASED NEURONAL NETWORK FUNCTION IN ADULT BRAIN"
"FAT MALABSORPTION","3","11.3773410450789","0.0517451418767487","75","lipf, sar1b, srp54","INDUCTION MICROVESICULAR FAT"
"GO:0006898","8","11.4390471715086","0.107627935336604","21.05","ap2b1, cd63, hsp90b1, hyou1, insra, rab5ab, rac1a, wnt3a","REDUCTION VITELLOGENIN ACCUMULATION INTO OOCYTES AND OOCYTE GROWTH/DEVELOPMENT; INCREASED LDL UPTAKE"
"ABNORMALITY OF REPRODUCTIVE SYSTEM PHYSIOLOGY","14","11.4838555539518","0.0441827948785113","13.59","cyb5a, eif2b4, fgfr1b, impdh1b, nek2, nr3c1, nras, nup107, papss2b, phgdh, rbm28, rras, snrpb, stub1","N/A IMPAIRMENT OF REPRODUCTIVE CAPACITY"
"GO:0005515","9","11.5386819708517","0.0537995009947494","19.15","cdc42, fgfr1b, fgfr4, ran, robo3, ta, tcf7l1a, thraa, vegfaa","BINDING SH-/SELEN-PROTEINS; COVALENT BINDING PROTEIN"
"ABNORMAL LUNG MORPHOLOGY","28","11.5498572784042","0.0273984302070358","21.88","atp6v1e1b, cdc42, ctsc, dhcr7, dkc1, exosc9, fgfr1b, lipf, mif, nfe2l2a, nfkb1, nras, nup107, phgdh, plod1a, ptenb, puf60a, rac1a, rps15a, rras, scn1lab, snrpb, srp54, stk11, sult2st3, tars, tbx20, tgfb2","INCREASE ADENOMAS/CARCINOMAS BRONCHIOLOALVEOLAR"
"GO:0003824","9","11.5584488728781","0.0739447707912407","13.85","ckbb, echs1, gcat, hmgcl, impdh1b, ldha, ppm1aa, sucla2, uqcrc1","DECREASED DHB4/HSD17B4; DECREASE INCORPORATION OF ACTIVE IODIDE INTO IODOTYROSINES; INHIBITION PROLYL HYDROXYLASES; INHIBITION UROD; DECREASE AKT/ENOS ACTIVITY; INHIBITION DEIODINASE 2; INHIBITION DEIODINASE 1; INHIBITION IODOTYROSINE DEIODINASE IYD; INHIBITION DEIODINASE 3; INHIBITION DUAL OXIDASE; INDUCTION UPREGULATION OF GLUCURONYLTRANSFERASE ACTIVITY"
"GO:0048870","32","11.5617095497884","0.0193265498391354","16","akt3a, bves, cd63, cdc42, dusp3a, EPHA2_2of2, fbxo5, fgfr1b, fgfr4, flt1, gbx2, gna12a, hmox1a, insra, ldha, lgmn, mapk3, mif, mmp28, nfe2l2a, nup85, onecut1, rac1a, rras, src, tbx20, tek, tgfb2, tradd, tspo, tubb2, xbp1","INCREASED MOTILITY"
"REGULATION OF CELL DEATH","36","11.8214564933371","0.0209704607430699","13.43","adcyap1b, adora2aa, ap2b1, apaf1, cdc42, cebpb, cops5, ctsc, ctsd, eno1a, fgfr1b, hmox1a, hsp90b1, hyou1, ldha, lgmn, mif, nfe2l2a, nfkb1, pa2g4b, pparab, ppp2r1b, ppp5c, psmd10, ptenb, rpl26, src, tek, tgfb2, thraa, tradd, tspo, vegfaa, wnt3a, xbp1, ywhaqb","N/A CELL INJURY/DEATH"
"BLADDER CANCER","3","11.8575710823985","0.0195401875392588","7.14","nras, src, vegfaa","INCREASE CANCER"
"CTOME VEGFR2 MEDIATED CELL PROLIFERATION","3","11.8575710823985","0.0195401875392588","50","nras, src, vegfaa","INHIBITION VEGFR2"
"GO:0030154","10","11.8660226666146","0.0752719240377566","15.38","fgf3, fstb, nr2f5, onecut1, pparab, rxrab, src, thraa, thrab, vegfaa","DIFFERENTIATION OF MYOFIBROBLAST"
"GO:0040011","35","11.9801339711925","0.0191735088925414","15.42","adora2aa, akt3a, bves, cd63, cdc42, dusp3a, EPHA2_2of2, fbxo5, fgfr1b, fgfr4, flt1, gbx2, gna12a, hmox1a, insra, ldha, lgmn, mapk3, mif, mmp28, nfe2l2a, nup85, onecut1, rac1a, robo3, rras, src, tbx20, tek, tgfb2, tradd, tspo, tubb2, wnt3a, xbp1","INCREASED LOCOMOTION; INCREASED MUSCULAR WAVES IN FOOT; DECREASED LOCOMOTION"
"OXIDATIVE STRESS","4","12.0591289981227","0.041620713312402","16.67","gsr, hmox1a, nfe2l2a, nfkb1","PROPAGATION OXIDATIVE STRESS; N/A OXIDATIVE STRESS; INCREASE OXIDATIVE STRESS / ACTIVATION PMK-1 P38 MAPK; INCREASED OXIDATIVE STRESS; INCREASE OXIDATIVE STRESS / ACTIVATION PMK-1 P38 MAPK; INCREASE ENERGETIC DEMANDS AND THEREFORE METABOLIC STRESS; INCREASED ENERGETIC DEMANDS AND THEREFORE METABOLIC STRESS"
"GO:0042060","14","12.284682021633","0.0362084974968863","15.91","adora2aa, cdc42, gna12a, hmox1a, mapk3, nfe2l2a, papss2b, pparab, rab5ab, rac1a, src, tgfb2, wnt3a, xbp1","FAILURE IN VASCULAR REPAIR MECHANISMS UNRESOLVED BLOOD LOSS HEMORRHAGE"
"GO:0016209","2","12.3128212166539","0.0335037275418397","18.18","gsr, gstk1","OXIDATION GLUTATHIONE"
"G GLUTATHIONE METABOLISM","2","12.3128212166539","0.0335037275418397","25","gsr, gstk1","DEPLETION GSH"
"GO:0045444","3","12.3469553923051","0.40486019461269","7.32","cebpb, wnt3a, xbp1","INCREASED ADIPOGENESIS"
"ABNORMALITY OF THE OVARY","7","12.579994931897","0.124393701180334","12.28","cyb5a, eif2b4, fgfr1b, flt1, nup107, ptenb, stk11","REDUCED PROSTAGLANDINS OVARY"
"NRF2 PATHWAY","5","12.6023519721413","0.0365107003892799","12.5","EPHA2_2of2, gsr, hmox1a, nfe2l2a, tgfb2","ACTIVATION NRF2"
"GO:0009790","21","12.6713585407248","0.0443998704953805","12.43","apaf1, cebpb, cpt2, EPHA2_2of2, fgfr1b, flt1, gbx2, gna12a, hoxb5a, hoxb8a, insra, mapk3, nek2, nfe2l2a, phgdh, rdh10a, rnf2, tbx20, tgfb2, tubb2, wnt3a","DEFECT OF EMBRYOGENESIS"
"RESPONSE TO ESTRADIOL","3","13.2003237629029","0.321298479385975","10","igfbp2a, pcna, ptenb","REDUCTION PLASMA 17BETA-ESTRADIOL CONCENTRATIONS"
"CYANOSIS","4","13.2857444304907","0.169584214765307","21.05","cyb5a, cyb5r3, scn1lab, tbx20","N/A CYANOSIS OCCURS"
"GO:0048469","4","13.291678250008","0.0949776869610552","16.67","fbxo5, fgfr1b, ppp2r1b, xbp1","INCREASED OOCYTE MATURATION"
"ABNORMAL OVARIAN MORPHOLOGY","6","13.3590075243329","0.158477093315406","16.22","cyb5a, fgfr1b, flt1, nup107, ptenb, stk11","PROMOTION OVARIAN GRANULAR CELL TUMORS; DECREASED OVARIAN E2; PROMOTION OVARIAN ADENOMAS"
"CTOME RHO GTPASES ACTIVATE NADPH OXIDASES","2","13.3968343160699","0.202993072773091","33.33","mapk3, rac1a","ACTIVATION NADPH OXIDASE"
"GO:0001935","8","13.4056337805188","0.0771232883315354","22.22","akt3a, EPHA2_2of2, fgfr1b, flt1, hmox1a, nras, tek, xbp1","INCREASED PROLIFERATION ENDOTHELIAL CELLS"
"GLUTATHIONE METABOLIC PROCESS","3","13.6453901747149","0.0302215480814948","30","gsr, gstk1, nfe2l2a","GLUTATHIONE SYNTHESIS; GLUTATHIONE HOMEOSTASIS"
"GO:0019904","18","13.7712153140198","0.0333297033530818","14.63","calm1b, cdc42, fgfr1b, insra, llgl2, nfe2l2a, pparab, rnf2, rqcd1, skp1, src, stk11, stub1, thraa, tradd, u2af2b, wnt3a, ywhaqb","N/A INTERFERENCES WITH SH-/SELEN-PROTEINS"
"REGULATION OF WNT SIGNALING PATHWAY","12","13.7824003147621","0.051768802484688","15.19","csnk1g2a, igfbp2a, nfkb1, ppm1aa, ppp2r1b, psmd10, psmd13, psmd4a, src, stk11, tcf7l1a, wnt3a","INHIBITION WNT PATHWAY"
"GO:0003158","3","13.8488671417138","0.282638896088729","12.5","fasn, hoxb5a, rap1aa","IMPAIRMENT ENDOTHELIAL NETWORK"
"GO:0046983","23","14.0916958102518","0.030752275268975","11.68","adora2aa, cebpb, eno1a, fasn, fgfr1b, hmgcl, hmox1a, nfkb1, plod1a, polr2c, ppp2r1b, prmt5, ran, rchy1, rpl7, rqcd1, stub1, taf11, tars, tgfb2, ttk, tubb2, xbp1","DIMERIZATION AHR/ARNT; REDUCED DIMERIZATION ARNT/HIF1-ALPHA"
"GO:0050663","4","14.4693451453502","0.0618246531995863","13.33","mapk3, mif, src, xbp1","RELEASE CYTOKINE"
"GO:0050673","14","14.5856538558896","0.0514116362640997","17.07","akt3a, cdc42, cebpb, EPHA2_2of2, fgfr1b, flt1, hmox1a, nras, stk11, tek, tgfb2, wnt3a, xbp1, ywhaqb","INCREASE REGENERATIVE CELL PROLIFERATION TUBULAR EPITHELIAL CELLS; INCREASE REGENERATIVE CELL PROLIFERATION TERMINAL BRONCHIOLAR EPITHELIAL CELLS"
"GO:0007269","3","14.7376510271225","0.234803579668545","12","adora2aa, rab5ab, rap1aa","OVERACTIVATION NEURONOTRANSMITTER RELEASE"
"MORTALITY AGING","7","14.8316948707725","0.0593613775755732","26.92","hmgcl, hyou1, lipf, nras, ogdhb, phgdh, snrpb","REDUCED FITNESS OR EVEN MORTALITY ACIDOSIS HYPOVOLEMIC SHOCK AND ORGAN DYSFUNCTION; INCREASE MORTALITY; INCREASED MORTALITY"
"GO:0007009","2","15.2298213373741","0.0819503951655871","22.22","SERP1, tgfb2","NARCOSIS"
"GO:0048856","3","15.2468941717854","0.404298979198395","25","insra, nr2f5, rxrab","ALTERED NEUROANATOMY"
"GO:0044703","13","15.308520066261","0.0694712842470538","11.21","adcyap1b, fbxo5, igfbp2a, mapk3, nhp2l1b, ppat, ppp2r1b, rnf2, rpl39, src, stk11, thraa, ttk","N/A REPRODUCTIVE FAILURE"
"GO:1903009","3","15.6676535970299","0.135813620649403","8.82","psmc1a, psmd13, psmd4a","DECREASE GTPCH-1"
"GO:0007249","5","15.7351935206704","0.0476920730516745","11.63","hmox1a, nfkb1, ppm1aa, ppp5c, tradd","INHIBITION NUCLEAR FACTOR KAPPA B NF-KB"
"GO:0001816","19","16.1169421765573","0.0321077011249535","15.83","adcyap1b, cebpb, EPHA2_2of2, fgfr1b, hmox1a, lipf, mapk3, mif, nfkb1, nploc4, polr2eb, polr2l, polr3d, rac1a, src, tgfb2, tspo, wnt3a, xbp1","NON-NEURONAL PRODUCTION OF TNF EPITHELIAL IRRITATION; PRODUCTION OF NERVE GROWTH FACTOR  EPITHELIAL IRRITATION; NON-NEURONAL PRODUCTION OF IL-8/CXCL1 EPITHELIAL IRRITATION"
"GO:0046903","34","16.3167626919054","0.017950347286158","14.72","adcyap1b, adora2aa, apaf1, atp5j, atp6ap1b, calm1b, cd63, cops5, ctsc, ctsd, cyb5r3, cyp51, fgfr1b, glud1a, hmox1a, impdh1b, llgl2, mapk3, mif, mvp, ndufc2, nfkb1, nras, pa2g4b, ppat, psmd13, rab5ab, rac1a, rap1aa, SERP1, src, tardbp, tgfb2, xbp1","SUPPRESSION VLDL SECRETION; INCREASE MUCIN PRODUCTION; INCREASED SECRETION OF LOCAL GROWTH FACTORS"
"ABNORMAL FORM OF THE VERTEBRAL BODIES","6","16.3564927716295","0.0878397179972633","18.18","dhcr7, fgfr1b, papss2b, ptenb, puf60a, srp54","CLONAL EXPANSION/CELL PROLIFERATION TO FORM ALTERED HEPATIC FOCI AHF"
"SOMATIC MUTATION","5","16.5336362844442","0.135083565185818","5.95","fgfr1b, nras, ptenb, src, stk11","INCREASED INDUCED MUTATIONS IN CRITICAL GENES; INCREASE MUTATIONS; INCREASE MUTATIONS IN CRITICAL GENES"
"GO:0007568","10","16.732884855234","0.0405377566314226","11.63","akt3a, apaf1, ctsc, fbxo5, igfbp2a, mapk3, mif, nfe2l2a, SERP1, tspo","ACCELERATED AGING"
"GO:0009611","16","17.3014267854262","0.0389251010351545","14.29","adora2aa, cdc42, dhfr, gna12a, hmox1a, mapk3, nfe2l2a, papss2b, pparab, rab5ab, rac1a, src, tgfb2, tspo, wnt3a, xbp1","ACCUMULATION DAMAGED MITOCHONDRIAL DNA"
"GO:0001775","29","17.3043984036584","0.0180344368440281","14.8","adora2aa, apaf1, cd63, cdc42, cebpb, ctsc, ctsd, cyb5r3, dusp3a, gna12a, hmox1a, igfbp2a, impdh1b, mapk3, mif, mvp, ndufc2, nfkb1, nras, onecut1, pa2g4b, prmt5, psmd13, rac1a, rap1aa, src, stk11, wnt3a, xbp1","ACTIVATION DENDRITIC CELLS"
"HYPERACTIVITY","9","17.3589682492938","0.0581958234947885","18","dhcr7, fgfr1b, glud1a, ppp2r1b, puf60a, scn1lab, snrpb, tlk2, tubb2","INDUCTION ATAXIA PARALYSIS OR HYPERACTIVITY; INCREASED ATAXIA PARALYSIS OR HYPERACTIVITY; N/A ATAXIA PARALYSIS OR HYPERACTIVITY"
"APOPTOSIS","3","17.4572372159197","0.0464110393206392","5.36","apaf1, nfkb1, tradd","INCREASED APOPTOSIS ADENOMAS/CARCINOMAS FOLLICULAR CELL"
"CTOME FOXO MEDIATED TRANSCRIPTION","4","17.5590929943342","0.161671850585406","14.29","akt3a, nr3c1, stk11, ywhaqb","ACTIVATION FOXO"
"MICROTUBULE POLYMERIZATION OR DEPOLYMERIZATION","2","17.8354127158801","0.115113151051247","20","fbxo5, rac1a","DEPOLYMERIZATION MICROTUBULE"
"GO:0005102","21","18.572318370923","0.0313483172935315","10.1","adcyap1b, adora2aa, cdc42, cebpb, dusp3a, fgf3, fgfr1b, gna12a, hsp90b1, igfbp2a, insra, mif, pcna, ran, rqcd1, src, stub1, taf11, tgfb2, tradd, wnt3a","DECREASED TESTOSTERONE BINDING TO ANDROGEN RECEPTOR HYPOTHALAMUS"
"CTOME ACTIVATION OF GENE EXPRESSION BY SREBF SREBP","4","18.6171739069361","0.132468469791905","33.33","cyp51, dhcr7, fasn, pparab","UP REGULATION SREBF2"
"STEROID HORMONE MEDIATED SIGNALING PATHWAY","5","18.7782329174874","0.0935699900478994","4.9","nr3c1, pparab, ppp5c, rqcd1, src","DECREASE STEROIDOGENIC ACUTE REGULATORY PROTEIN STAR; DECREASED HSD17B10 EXPRESSION; REDUCED MATURATION INDUCING STEROID PLASMA"
"GO:0006281","12","18.9245574477081","0.0495099723576979","14.12","cops5, nploc4, pcna, pold2, polr2c, polr2eb, polr2l, ppp5c, rchy1, rfc5, rpa2, stub1","N/A INSUFFICIENT OR INCORRECT DNA REPAIR; INCREASED INSUFFICIENT REPAIR OR MIS-REPAIR OF PRO-MUTAGENIC DNA ADDUCTS; OVERWHELMED MITOCHONDRIAL DNA REPAIR MECHANISMS; INCREASED DNA DAMAGE-REPAIR"
"GO:0006954","16","19.0124438463072","0.0405259377586848","13.68","adcyap1b, adora2aa, ahcy, cebpb, ctsc, EPHA2_2of2, hmox1a, lipf, mif, nfe2l2a, nfkb1, pparab, rac1a, scn1lab, tek, tradd","INCREASE INFLAMMATION; INCREASE INFLAMMATION CORNEAL CELLS; INFILTRATION INFLAMMATORY CELLS; INCREASED INFLAMMATION; CHRONIC COUGH RESPIRATORY IRRITABILITY"
"ABNORMAL CIRCULATING FATTY ACID CONCENTRATION","2","19.2627298388254","0.0876832819144008","22.22","cpt2, hmgcl","ACCUMULATION FATTY ACID"
"DECREASED PLASMA CARNITINE","2","19.2627298388254","0.0876832819144008","28.57","cpt2, hmgcl","REDUCTION PLASMA VITELLOGENIN CONCENTRATIONS; INCREASE PLASMA VITELLOGENIN CONCENTRATIONS; DECREASED RENAL PLASMA FLOW; INCREASED PLASMA TYROSINE; DECREASED PROSTAGLANDIN F2ALPHA CONCENTRATION PLASMA"
"GO:0015908","4","19.4849911987996","0.0254188336277958","18.18","atp5j, cpt2, mif, pparab","INCREASED FA INFLUX"
"GO:0000003","24","19.991677328803","0.0364428285093741","11.82","adcyap1b, cebpb, eif2b4, fbxo5, igfbp2a, insra, ldha, mapk3, nek2, nhp2l1b, nup107, pcna, ppat, ppp2r1b, psmd13, rdh10a, rnf2, rpl39, rqcd1, src, stk11, tgfb2, thraa, ttk","REDUCED REPRODUCTIVE SUCCESS; REPRODUCTIVE FAILURE"
"CTOME CELLULAR RESPONSE TO HYPOXIA","4","20.1305152459798","0.0709320705340065","9.3","psmd10, psmd13, psmd4a, vegfaa","N/A HYPOXIA"
"RESPONSE TO REACTIVE OXYGEN SPECIES","9","20.206954444503","0.0928319243460969","16.07","dhfr, hmox1a, ldha, mapk3, nfe2l2a, pcna, ppp5c, slc8a1a, src","INCREASED REACTIVE OXYGEN SPECIES"
"GO:0006915","3","21.333626565792","0.0348290252727655","9.68","apaf1, bcl2a, tradd","CHANGES/INHIBITION CELLULAR HOMEOSTASIS AND APOPTOSIS; DECREASED APOPTOSIS EPITHELIAL CELLS; INCREASED APOPTOSIS DECREASED LEYDIG CELLS"
"GO:0006936","4","21.7809906011037","0.139984234713297","7.27","calm1b, eno1a, scn1lab, tbx20","REDUCTION ABDOMINAL MUSCLE CONTRACTION; OVERACTIVATION MUSCLE CONTRACTION"
"OXIDATIVE DAMAGE","4","22.3196794312596","0.143710018861419","20","apaf1, cdc42, nfkb1, pcna","INCREASED OXIDATIVE DAMAGE"
"JNK CASCADE","3","22.7751395357297","0.166943132407333","13.64","cdc42, cops5, dusp3a","ACTIVATION JNK"
"GO:0006633","5","23.1718053232621","0.1143337465386","17.24","cyp3c1, fasn, mif, ptges3a, xbp1","SYNTHESIS DE NOVO FA; INCREASED DE NOVO FA SYNTHESIS; INCREASED DE NOVO FA SYNTHESIS"
"LUNG FIBROSIS","3","24.5502000783934","0.216085836905764","8.33","cebpb, hmox1a, nfe2l2a","LUNG FIBROSIS"
"REGULATION OF POTASSIUM ION TRANSPORT","3","24.8966215189766","0.329441378553647","18.75","adcyap1b, cd63, ptenb","INHIBITION ETHER-A-GO-GO ERG VOLTAGE-GATED POTASSIUM CHANNEL"
"GO:0060291","2","25.0149981412002","0.411379307302863","14.29","adora2aa, lgmn","DECREASED LONG-TERM POTENTIATION LTP"
"GO:1903008","2","25.0675789069208","0.610524134344219","15.38","ctsk, tspo","DISRUPTION LYSOSOME"
"GO:0007588","2","25.7272515659606","0.402757612161234","14.29","adora2aa, hmox1a","INCREASE BILIARY EXCRETION TH GLUCURONIDE"
"GO:0006839","5","28.8790243161823","0.094592454823131","10.87","atp5j, cpt2, tomm34, tspo, ywhaqb","REDUCTION CHOLESTEROL TRANSPORT IN MITOCHONDRIA"
"GO:0019932","4","29.1887504314252","0.192766886414448","6.56","adcyap1b, adora2aa, calm1b, ppp2r1b","INCREASED SECOND MESSENGER PRODUCTION"
"ARYL HYDROCARBON RECEPTOR PATHWAY","3","32.6461868960709","0.198116234598913","6.25","nfe2l2a, ptges3a, src","UP REGULATION CYP1A1; ACTIVATION AHR"
"ABNORMALITY OF THE BLADDER","6","33.4505004749991","0.083092524139285","11.54","glud1a, plod1a, puf60a, scn1lab, stk11, stub1","REDUCED POSTERIOR SWIM BLADDER INFLATION; REDUCED ANTERIOR SWIM BLADDER INFLATION; INCREASE URINARY BLADDER CALCULI"
"GO:0048813","2","34.1804519188361","0.463271172943807","15.38","cdc42, stk11","ABERRANT DENDRITIC MORPHOLOGY"
"GO:0042698","3","34.2360936237616","0.190160496725876","13.64","pcna, src, tgfb2","IRREGULARITIES OVARIAN CYCLE"
"GO:0030520","2","36.6568439149875","0.314218838306637","25","rqcd1, src","ACTIVATION ESTROGEN RECEPTOR ALPHA"
"ABNORMAL CORNEAL EPITHELIUM MORPHOLOGY","2","37.4119100612702","0.384658971459278","15.38","scn1lab, tars","INCREASED ACCUMULATION OF ALPHA2U MICROGLOBULIN PROXIMAL TUBULAR EPITHELIUM"
"GO:0030331","2","44.9191183519195","0.376639504904676","22.22","pcna, src","INCREASED ER BINDING TO DNA CLASSICAL PATHWAY; INCREASED ER BINDING TO TF TO DNA NON-CLASSICAL PATHWAY"
"GO:0042446","4","45.2970151822744","0.128778427786574","14.29","cyp3c1, dhcr7, nfkb1, tspo","INCREASE LUTEINIZING HORMONE LH; REPRESSED EXPRESSION OF STEROIDOGENIC ENZYMES"
"REGULATION OF NITRIC OXIDE SYNTHASE ACTIVITY","2","45.3768254036242","0.451740698952144","25","calm3a, dhfr","INHIBITION INDUCIBLE NITRIC OXIDE SYNTHASE BY METABOLITE CGA 265307"
"BRADYCARDIA","3","50.9935930851881","0.200218307305785","50","bves, calm3a, scn1lab","INCREASED ATRIOVENTRICULAR BLOCK AND BRADYCARDIA"
"GO:0006636","2","53.4127491436086","0.332217999490632","16.67","mif, ptges3a","UP REGULATION UNSATURATED FATTY ACID"
"GO:1903409","3","53.9633306803796","0.154129045295655","12","insra, rac1a, tspo","INCREASE ROS PRODUCTION; PRODUCTION REACTIVE OXYGEN SPECIES"
"DRUG INDUCTION OF BILE ACID PATHWAY","2","59.1650816956625","0.295438195045012","16.67","cyp3c1, sult2st3","DECREASED BILE FLOW"
"FARNESOID X RECEPTOR PATHWAY","2","59.1650816956625","0.295438195045012","20","cyp3c1, sult2st3","ACTIVATION NR1H4"
"GO:0051899","4","74.100515444554","0.128290471071209","19.05","adora2aa, scn1lab, src, tspo","OCCURRENCE A PAROXYSMAL DEPOLARIZING SHIFT; PROLONGED DEPOLARIZATION OF NEURONAL MEMBRANE"
"SYNAPTIC TRANSMISSION GLUTAMATERGIC","2","128.161236163613","0.0903527023634656","15.38","adcyap1b, adora2aa","REDUCED PRESYNAPTIC RELEASE OF GLUTAMATE"
